Darusentan: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''darusentan''' is a medication for hypertension that is a selective endothelin type A antagonist. It is a vasodilator.<ref name="10.1016/S0140-6736(09)61500-2">Weber MA ...) |
imported>Robert Badgett mNo edit summary |
||
| Line 1: | Line 1: | ||
In [[medicine]], '''darusentan''' is a medication for hypertension that is a selective endothelin type A antagonist. It is a vasodilator.<ref name="10.1016/S0140-6736(09)61500-2">Weber MA et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet {{doi|10.1016/S0140-6736(09)61500-2}}</ref> | In [[medicine]], '''darusentan''' is a [[medication]] for treating [[hypertension]] that is a selective endothelin type A antagonist. It is a vasodilator.<ref name="10.1016/S0140-6736(09)61500-2">Weber MA et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet {{doi|10.1016/S0140-6736(09)61500-2}}</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 22:09, 14 September 2009
In medicine, darusentan is a medication for treating hypertension that is a selective endothelin type A antagonist. It is a vasodilator.[1]
References
- ↑ Weber MA et al. (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet DOI:10.1016/S0140-6736(09)61500-2